BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab |
| April 14, 2020 | April 2020 Bond Updates |
|
LUND, Sweden, April 14, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today provides a preliminary insight into progress of its Phase I/IIa trial of BI-1206 in combination with rituximab for treatment of Non-Hodgkin Lymphoma (NHL). In the... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvent-reports-promising-progress-in-phase-illa-trial-of-lead-program-bi-1206-in-combination-with-rituximab-301039858.html |
| Related News |